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Three genome-wide association studies in Europe and the USA have reported eight urinary bladder cancer
(UBC) susceptibility loci. Using extended case and control series and 1000 Genomes imputations of
5 340 737 single-nucleotide polymorphisms (SNPs), we searched for additional loci in the European GWAS.
The discovery sample set consisted of 1631 cases and 3822 controls from the Netherlands and 603 cases
and 37 781 controls from Iceland. For follow-up, we used 3790 cases and 7507 controls from 13 sample
sets of European and Iranian ancestry. Based on the discovery analysis, we followed up signals in
the urea transporter (UT) gene SLC14A. The strongest signal at this locus was represented by a SNP in
intron 3, rs17674580, that reached genome-wide significance in the overall analysis of the discovery and
follow-up groups: odds ratio 5 1.17, P 5 7.6 3 10211. SLC14A1 codes for UTs that define the Kidd blood
group and are crucial for the maintenance of a constant urea concentration gradient in the renal medulla
and, through this, the kidney’s ability to concentrate urine. It is speculated that rs17674580, or other
sequence variants in LD with it, indirectly modifies UBC risk by affecting urine production. If confirmed,
this would support the ‘urogenous contact hypothesis’ that urine production and voiding frequency
modify the risk of UBC.
INTRODUCTION
Globally each year, almost 400 000 new patients are diagnosed
with urinary bladder cancer (UBC) and more than 150 000
patients die from the disease (1,2). Most patients with UBC
are treated with conservative surgery but they experience an
extremely high risk of frequent recurrences. Because of that,
bladder cancer is the most expensive cancer in many Western
communities (3). Both in the USA and western Europe, 1 in
every 25 men and 1 in 80 women will develop bladder cancer
sometime during life (1). This 3:1 male/female ratio is largely
explained by historical differences in smoking habits and
occupational exposure to carcinogens, the most important risk
factors for UBC. Bladder cancer has historically not been
perceived as a disease with a strong genetic background, even
though high-risk UBC families have been identified (4). The
risk of UBC is increased almost 2-fold for first-degree relatives
of UBC cases but this clustering may largely be explained by
low-penetrance genetic polymorphisms (5–8). Candidate gene
association studies have consistently shown that NAT2 slow
acetylator and GSTM1 null genotypes increase UBC risk (9).
Dozens of other suggestions from such studies have not been
replicated. Recently, three genome-wide association studies
(GWAS) have identified eight additional UBC risk loci
2 Human Molecular Genetics, 2011
 by guest on June 1, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
(10–13) (Table 1). All of these loci have been extensively
replicated (12).
Here, we report on a new UBC susceptibility locus discov-
ered from an extension of the European UBC GWAS.
RESULTS
To search for variants that affect the risk of UBC, we imputed
1000 Genomes project’s single-nucleotide polymorphisms
(SNPs) into our two discovery data sets, composed of 603 Ice-
landic cases and 37 781 Icelandic controls and 1631 Dutch
cases and 3822 Dutch controls, genotyped on the Human-
Hap300 or HumanCNV370-duo BeadChips. For the Icelandic
data set, the imputation was done with version 3 of the
1000 Genomes data set, whereas version 2 was used for the
Dutch data set (see Materials and Methods). After excluding
SNPs that failed quality control in either of the data sets and
SNPs with minor allele frequency ,0.01, 5 340 737 SNPs
present in both data sets were included in a combined analysis
of the two sets. After excluding SNPs that showed associations
with significant heterogeneity between the two populations
and a single SNP, rs10094872, located at the previously
reported bladder cancer locus at 8q24 (10), no variants
reached genome-wide significance, here defined conserva-
tively as P, 1 × 1028 (¼0.05/5 million SNPs).
Assessing missense variants in protein-coding genes, we
noted that among the top variants were two SNPs located in
the solute carrier family 14, member 1 (SLC14A1 or UT-B)
gene, a member of the SLC14A family of urea transporters
(UTs) crucial to the kidney’s ability to concentrate urine.
The gene is also expressed on red blood cells where different
isoforms, defined by two alleles Jka and Jkb, form the Kidd
blood group system (14). The G allele of marker rs1058396
(rs1058396[G], SLC14A1 D280N) showed an odds ratio
(OR) of 1.16 and a P-value of 3.4 × 1025, whereas
rs11877062[C] (SLC14A1 R4W) had an OR of 1.15 and a
P-value of 9.8 × 1025. The SNP that showed the stronger
association with UBC, rs1058396[G], causes the amino acid
change D280N which defines the two alleles of the Kidd
blood group system (15). Since the two missense variants
are highly correlated (r2¼ 0.88 based on the 566
chromosomes in the 1000 Genomes version 3 training set),
subsequent follow-up studies focused on rs1058396
(D280N). Before proceeding to such follow-up studies,
however, we scrutinized the association results between
UBC and all tested SNPs in a 0.5 Mb region centered on
rs1058396 (Fig. 1). Apart from rs1058396 (D280N) and
rs11877062 (R4W), a total of 35 markers had P-values
lower than 1.0 × 1024 (Supplementary Material, Table S1)
and of those, 18 were strongly correlated with the coding
SNPs (r2. 0.8). For follow-up, we also selected the SNP
rs17674580 as a representative of a group of 10 correlated
SNPs that did not correlate well with rs1058396 (r2 ≈ 0.5).
rs17674580 is located in an intron of SLC14A1, 12 kb cen-
tromeric to rs1058396 (D280N) (Fig. 1). The LD block where
both rs17674580 and rs1058396 (D280N) are located contains
only the SLC14A1 gene (Fig. 1). After adjusting for either
rs1058396 or rs17674580, only one of the other 35 SNPs
associated with UBC with nominal significance and none
after adjusting for the number of SNPs (Supplementary
Material, Table S1).
We genotyped both rs17674580 and rs1058396 (D280N) in
13 additional UBC case–control sample sets from Iceland,
Italy, the UK, Spain, Sweden, Belgium, Germany, Eastern
Europe and Iran (Table 2). Both SNPs replicated in the
follow-up groups combined and both reached GW significance
in the overall analysis of the discovery and follow-up groups
with an OR of 1.17 and a P-value of 7.6 × 10211 for
rs17674580[T] and an OR of 1.14 and a P-value of 2.9 ×
1029 for rs1058396[G]. We did not observe significant hetero-
geneity of the ORs between studies [Phet ¼ 0.10 and 0.54,
I2 ¼ 33.0 and 0 for rs17674580 and rs1058396 (D280N),
respectively]. Relative to the non-carriers, the ORs for hetero-
zygous and homozygous carriers of the rs17674580[T] were
estimated to be 1.17 and 1.37, respectively.
We examined the joint effect of rs17674580[T] and
rs1058396[G] using samples directly genotyped by a single-
track assay for both SNPs (Table 3). After adjusting for
rs1058396[G] (D280N), the association of rs17674580[T]
remained significant (OR ¼ 1.1, 95% CI 1.03–1.18,
P ¼ 0.0061), whereas the association between rs1058396[G]
(D280N) and UBC almost disappeared after adjustment for
rs17674580[T].
Table 1. Extensively replicated UBC susceptibility loci
Locus Gene region SNP Risk allelea Allelic OR Risk allele frequency Reference Replicated by
8q24.21 MYC rs9642880 T 1.22 0.45 (10) (12,13,39,50,51)
3q28 TP63 rs710521 A 1.19 0.73 (10) (12,13,37)
5p15.33 TERT rs2736098 A 1.12b 0.26 (52) (53)
5p15.33 CLPTM1L rs401681 C 1.07b 0.54 (52) (12,53)
8q24.3 PSCA rs2294008 T 1.15 0.46 (13) (12,54)
4p16.3 TACC3-FGFR3 rs798766 T 1.24 0.19 (11) (12,55)
22q13.1 CBX6, APOBEC3A rs1014971 T 1.14 0.62 (12) (12) included data from (11,13)
19q12 CCNE1 rs8102137 C 1.13 0.33 (12) (12) included data from (11,13)
2q37.1 UGT1A rs11892031 A 1.19 0.92 (12) (12) included data from (11,13)
8p22 NAT2 rs1495741 A 1.15 0.80 c (12)
1p13.3 GSTM1 — Null 1.47 0.51 c (12)
aFor GSTM1, these do not refer to the risk allele but to the risk genotype.
bReported ORs are mutually adjusted for rs401681 and rs2736098.
cThese susceptibility loci have frequently been reported by candidate gene association studies, using different assays.
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We have previously reported a UBC risk variant at the
FGFR3/TACC3 locus at 4p16 that shows significantly stronger
association with UBC with a predicted ‘low risk’ of pro-
gression (tumors confined to the bladder mucosa and not
poorly differentiated) than with UBC with a predicted ‘high
risk’ of progression (tumor invasion in or beyond the lamina
propria or poorly differentiated). Using the same classification
of cases, we found that the frequency of rs17674580[T] did not
differ between patients with tumors of different aggressiveness
(combined OR high versus low risk ¼ 1.07, P ¼ 0.17,
Table 4). By regressing on the age at diagnosis for 4750
cases, we found that rs17674580[T] did not associate with
age at diagnosis of UBC (effect ¼ 20.25 years per allele;
P ¼ 0.27, Phet ¼ 0.33).
Since smoking is a strong risk factor for UBC and variants
in the sequence of the genome that affect smoking
behavior have been identified, we tested whether either
rs17674580[T] or rs1058396[G] (D280N) was associated
with smoking behavior, using genotypes and information on
smoking from 17 617 Icelanders who have a history of
smoking (16). Neither rs17674580[T] nor rs1058396[G]
(D280N) associated with smoking quantity as measured by
number of cigarettes smoked per day [P ¼ 0.94 and 0.88 for
rs17674580[T] and rs1058396[G] (D280N), respectively].
Finally, we tested for association between rs17674580[T]
and serum urea in an Icelandic sample set that had urea
measurements (n ¼ 3641) (17). No significant association
between blood urea and rs17674580 was observed (P ¼ 0.68).
DISCUSSION
Urea is produced in the liver as the main nitrogenous end
product of protein catabolism. Depending on the diet, 20–
30 g of urea is produced per day and passed into the blood.
It is filtered in the kidney and either excreted or absorbed
and concentrated in the renal medulla in order to negate the
osmotic effect of urea in the urine and thereby maintain
body fluid balance (18). Specific proteins, called facilitative
UTs, mediate urea flux across cellular membranes, necessary
for the process of concentrating urine and salvaging nitrogen.
These proteins are derived from two distinct genes, Solute
Carrier Family 14, member 1; SLC14A1 (or UT-B) and
SLC14A2 (or UT-A). The genes occur in tandem on chromo-
some 18q12.1–q21.1 and are probably the result of dupli-
cation of a primordial UT gene (19). UT-A and UT-B
Figure 1. A schematic view of the structure and association results in the UBC-associated region on chromosome 18q12.3. (A) Estimated recombination rates
(saRR) in cM/Mb from the HapMap (release 22) Phase II data. (B) Location of known genes in the region. (C) Schematic view of the association with bladder
cancer for all SNPs tested in the region for the initial scan (Iceland and the Netherlands). The y-axis indicates the –log 10 P-value. Red dots indicate SNPs
directly genotyped in both discovery series; blue dots indicate SNPs imputed in both discovery series; green dots indicate SNPs directly genotyped in the Ice-
landic series but imputed in the Dutch series.
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transporters have a similar basic structure and function but
there are also a number of significant differences. Whereas
UT-A transporters are mainly found in the kidney, UT-B
expression is mainly found on the erythrocyte plasma mem-
brane and, to a lesser extent, in the descending vasa recta of
the kidney, in the brain, ear, testis, intestine and urinary
bladder (18). Unlike UT-A, UT-Bs transport water in addition
to urea, have a higher transport rate, are inhibited by mercurial
compounds and are less acutely regulated (14).
Until now, no overt pathologies associated with defects in
urea transport are known. Several mutations in the UT-B
gene lead to expression of defective UT-B proteins and a
lack of urea transport in erythrocytes. People with such
UT-B mutations have red blood cells that are devoid of the
Kidd blood group antigen (i.e. JKnull) but further than that
there is no clear phenotypic effect. Only when JKnull individ-
uals are dehydrated, they appear to have a mild (20%)
reduction in maximal urinary concentrating capacity (20). In
agreement with this finding, studies in UT-B knockout mice
show a 45-fold reduction in red blood cell urea permeability,
50% increase in urine output and 30% decrease in urine
osmolality compared with WT mice (21). The UT-B null
Table 2. Association of rs1058396[G] and rs17674580[T] on 18q12.3 with UBC
Study population (n cases/n controls) rs1058396[G] rs17674580[T]
Frequency OR 95% CI P-value Info Frequency OR 95% CI P-value Info
Cases Controls Cases Controls
Discovery groups (GWA)
Iceland (603/37 781)a 0.531 0.487 1.20 1.06–1.34 2.5 × 1023 0.986 0.381 0.334 1.24 1.10–1.40 5.0 × 1024 0.992
The Netherlands (1631/3822)a 0.548 0.515 1.14 1.05–1.24 1.6 × 1023 1000 0.392 0.366 1.13 1.03–1.23 6.8 × 1023 0.987
Follow-up groups
Iceland II (178/2055)b 0.55 0.48 1.29 1.02–1.63 0.031 0.41 0.36 1.23 0.98–1.54 0.07
Iceland III (350/3500)b 0.50 0.48 1.18 1.05–1.34 0.0071 0.36 0.34 1.26 1.11–1.43 3.1 × 1024
UK (724/535) 0.56 0.55 1.04 0.89–1.22 0.65 0.38 0.38 1.01 0.85–1.19 0.93
Italy—Torino (328/389) 0.51 0.51 1.00 0.81–1.23 0.97 0.40 0.35 1.22 0.98–1.53 0.072
Italy—Brescia (181/192) 0.52 0.46 1.26 0.95–1.68 0.11 0.38 0.34 1.21 0.89–1.64 0.22
Belgium (191/378) 0.48 0.52 0.87 0.68–1.21 0.27 0.32 0.38 0.78 0.60–1.02 0.064
Eastern Europe (213/526) 0.52 0.48 1.19 0.94–1.49 0.15 0.37 0.34 1.17 0.92–1.48 0.20
Sweden (343/1264) 0.52 0.51 1.07 0.90–1.27 0.46 0.36 0.34 1.12 0.94–1.34 0.20
Spain (238/881) 0.56 0.52 1.20 0.97–1.48 0.085 0.37 0.35 1.07 0.87–1.32 0.52
Iran (269/246) 0.57 0.54 1.09 0.85–1.39 0.51 0.36 0.33 1.15 0.88–1.49 0.31
Germany—LW (213/198) 0.55 0.50 1.23 0.93–1.62 0.14 0.40 0.33 1.35 1.01–1.80 0.044
Germany—Dortmund (196/239) 0.55 0.49 1.29 0.99–1.69 0.059 0.41 0.32 1.45 1.09–1.92 9.5 × 1023
Germany—Neuss (216/104) 0.56 0.50 1.29 0.92–1.79 0.14 0.42 0.33 1.45 1.03–2.06 0.035
GWA (2234/41 603)c 1.16 1.08–1.24 3.4 × 1025 1.17 1.08–1.25 4.9 × 1025
Follow-up groups (3790/7507)c 1.13 1.07–1.20 2.5 × 1025 1.16 1.10–1.23 5.8 × 1027
All combined (6024/49 110)c 1.14 1.09–1.19 2.9 × 1029 1.17 1.11–1.22 7.6 × 10211
All P-values shown are two-sided. Shown are the corresponding numbers of cases and controls (n), allelic frequencies of variants in affected and control
individuals, the allelic odds-ratio (OR) with P-values based on the multiplicative model.
aResults presented for Iceland and the Netherlands were individually adjusted by the method of genomic control (see Materials and Methods).
bIceland II consists of cases and controls genotyped by single-SNP assay, Iceland III consists of cases and controls genotyped in silico, using genotype information
on relatives.
cFor the combined study populations, the control frequency was the average, unweighted control frequency of the individual populations, whereas the OR and the
P-values were estimated using the Mantel–Haenszel model.
Table 3. Joint analysis of rs17674580[T] and rs1058396[G] in UBC
Population rs17674580[T] adjusted for rs1058396[G] rs1058396[G] adjusted for rs17674580[T]
OR 95% CI P-value OR 95% CI P-value
The Netherlands 1.04 0.92–1.18 0.52 1.11 0.98–1.25 0.094
Iceland 1.17 0.99–1.37 0.063 1.08 0.92–1.27 0.36
Belgium 0.80 0.55–1.17 0.25 1.00 0.70–1.43 1.00
Germany—Lutherstadt–Wittenberg 1.34 0.88–2.02 0.17 0.99 0.67–1.49 0.98
Germany—Dortmund 1.42 0.95–2.13 0.08 1.03 0.70–1.52 0.89
Eastern Europe 1.17 0.82–1.67 0.39 1.04 0.73–1.47 0.83
Iceland II 1.13 0.79–1.62 0.52 1.19 0.83–1.70 0.34
Iran 1.14 0.81–1.61 0.46 0.99 0.71–1.38 0.97
Italy—Brescia 0.99 0.63–1.55 0.97 1.30 0.85–1.99 0.23
Italy—Torino 1.33 0.97–1.83 0.07 0.85 0.63–1.16 0.30
Germany—Neuss 1.39 0.85–2.27 0.19 1.07 0.67–1.71 0.77
Spain 1.02 0.75–1.38 0.91 1.15 0.85–1.54 0.36
Sweden 1.18 0.91–1.54 0.20 0.94 0.73–1.21 0.63
UK 0.96 0.77–1.21 0.76 1.07 0.86–1.34 0.53
Combined 1.1 1.03–1.18 0.0061 1.06 1.00–1.14 0.069
Phet ¼ 0.62, I2 ¼ 0.0 Phet ¼ 0.97, I2 ¼ 0.0
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mice also gain less weight, which suggests that intestinal
UT-B plays an important role in weight gain. This observation
may also be caused by an adverse effect on general health but
the mice displayed no obvious signs of ill-health.
The UT-B (SLC14A1) gene consists of 11 exons covering
30 kb. The gene is known to produce two isoforms via alterna-
tive splicing: UT-B1, which consists of 389 amino acids, and
UT-B2, which consists of 445 amino acids. Both transporters
consist of 10 transmembrane-spanning domains, a large extra-
cellular loop containing an N-glycosylation site, plus intra-
cellular N and C termini (14). rs1058396 (the ‘Kidd blood
group polymorphism’) is a G-to-A transition at nucleotide
838, located in exon 8 of the gene. It results in an
asp280-to-asn (D280N) amino acid substitution and an MnlI
RFLP (15). Whereas it was this variant that made us focus
on this new bladder cancer locus, several other variants at
this locus show similar association with bladder cancer in
our discovery analysis. Moreover, analysis of one of those var-
iants, rs17674580, a variant that is only moderately correlated
with rs1058396, indicates that rs1058396 cannot fully account
for the observed association of this locus with bladder cancer.
When analyzing those two variants jointly, it appeared that
rs17674580 can account for the observed association with
rs1058396, although the converse is not true.
We do not have any evidence for functionality of
rs17674580 or markers in strong LD with it. It has been
reported that variants in the UT-A (SLC14A2) gene, residing
in the LD block next to the block containing UT-B
(SLC14A1), associate with blood urea nitrogen levels in a
Japanese population (22). In our study, neither rs17674580
nor other variants in the LD block containing SLC14A1 associ-
ated with serum urea levels. The UT-B (SLC14A1) gene is
expressed in the urinary bladder but no difference in
expression between normal and cancerous urothelial tissue
has been observed (http://www.ncbi.nlm.nih.gov/geoprofiles)
(23,24). Also, as far as we have known, there are no data avail-
able on expression differences in urothelium by rs1058396 or
rs17674580 genotype. It is not certain that SLC14A1 variants
have a direct effect on the urothelium. Possibly, the associ-
ation with UBC is indirect through urine concentration or fre-
quency of urination. It has long been suggested that the
amount of daily fluid intake may have an effect on the risk
of bladder cancer. The so-called urogenous contact hypothesis
states that high fluid intake may reduce exposure to carcino-
gens by diluting the urine and reducing the contact time
through increased micturition (25). Large prospective epide-
miological studies have yielded inconsistent results on this
topic (26,27) which may be related to the enormous methodo-
logical difficulties in studying this relationship in an observa-
tional setting. In an experimental model, however, it was
clearly shown that beagle dogs administered 4-aminobiphenyl
have decreased levels of urothelial DNA adducts with
increased voiding frequency, supporting the urogenous
contact hypothesis (28). Consequently, SLC14A1 variants
that influence the urea concentration gradient at the level of
the descending vasa recta blood vessels in the renal medulla
may modify the risk of UBC through an effect on urine pro-
duction. Unfortunately, we were not able to evaluate this
because data on daily fluid intake and voiding frequency
were not available in our study.
In summary, we have discovered an association between
genetic variants at the SLC14A1 locus at chromosome 18q
and the risk of UBC. The gene codes for UTs that define the
Kidd blood group and help maintain constant urea concen-
tration gradient in the renal medulla. It is speculated that
one or more sequence variants at this locus indirectly
modify UBC risk by affecting the urine production. If this is
correct, our finding supports the urogenous contact hypothesis
that urine production and voiding frequency modify the risk of
bladder carcinogens.
MATERIALS AND METHODS
Study subjects from Iceland
Records of all UBC diagnoses were obtained from the Icelandic
Cancer Registry (ICR) (http://www.krabbameinsskra.is). The
ICR contains all cancer diagnoses in Iceland from 1 January
1955. The ICR contained records of 1845 Icelandic UBC
patients diagnosed until 31 December 2009. Recruitment of
UBC cases was initiated in 2001 and included all prevalent
cases as well as newly diagnosed cases from that time. Patients
Table 4. Association of rs17674580[T] with risk of progression
Study population (n high risk/n low risk) rs17674580[T]
Frequency OR 95% CI P-value
High risk Low risk
Iceland (59/121) 0.34 0.42 0.72 0.44–1.15 0.17
The Netherlands (467/609) 0.41 0.39 1.10 0.92–1.31 0.29
UK (405/274) 0.38 0.37 1.05 0.84–1.31 0.66
Italy—Torino (112/152) 0.40 0.40 0.99 0.70–1.40 0.95
Italy—Brescia (126/53) 0.39 0.36 1.14 0.71–1.82 0.59
Eastern Europe (100/34) 0.41 0.34 1.33 0.75–2.36 0.33
Sweden (193/142) 0.38 0.35 1.11 0.80–1.52 0.53
Spain (135/28) 0.36 0.30 1.27 0.68–2.34 0.45
Germany—Lutherstadt–Wittenberg (142/65) 0.41 0.38 1.12 0.73–1.71 0.60
Germany—Dortmund (74/118) 0.43 0.39 1.14 0.75–1.73 0.54
Germany—Neuss (108/98) 0.46 0.39 1.34 0.90–1.98 0.15
All combined (1921/1694)a 0.40 0.37 1.07 0.97–1.18 0.17 Phet ¼ 0.68 I2 ¼ 0.0
aFor the combined study populations, the control frequency was the average, unweighted control frequency of the individual populations, whereas the OR and the
P-values were estimated using the Mantel–Haenszel model.
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were recruited by trained nurses on behalf of the patients’ treat-
ing physicians, through special recruitment clinics. Participants
in the study donated a blood sample and answered a lifestyle
questionnaire. A total of 603 patients (77% males; diagnosed
from December 1964 to December 2009) were included in a
genome-wide SNP genotyping effort, using the Infinium II
assay method and either the Sentrix HumanHap 300 or
HumanCNV370-duo BeadChip (Illumina). The median age at
diagnosis for all consenting cases was 67.8 years (range 20–
95 years) compared with 68.5 years for all UBC patients in
the ICR. The 37 781 controls (41% males; mean age 61
years; SD ¼ 21) used in this study consisted of individuals
from other ongoing GWAS at deCODE and represent .15%
of the adult population of Iceland. No individual disease
group is represented by .10% of the total control group.
Cancer patients (prostate, breast, colorectal and lung) were ana-
lyzed separately, and the frequency of the sequence variants
studied did not differ from other controls. Samples from pros-
tate, breast, colorectal and lung cancer patients as well as indi-
viduals used for the analysis of smoking variables come from
other ongoing project at deCODE Genetics. The study was
approved by the Data Protection Authority of Iceland and the
National Bioethics Committee. Written informed consent was
obtained from all patients, relatives and controls. Personal iden-
tifiers associated with medical information and blood samples
were encrypted with a third-party encryption system for
which the Data Protection Authority maintains the code.
In addition to the chip-genotyped case–control series that
was used for the discovery phase of the study (Iceland I),
we selected two follow-up (replication) case–control sample
sets. The first of these (Iceland II) consists of 178 UBC
cases and 2055 controls who were recruited after 2007 in
the same way as the group ‘Iceland I’ but who were not whole-
genome genotyped. This group was genotyped using
single-SNP assays. The second follow-up group (Iceland III)
was generated using information on 950 UBC cases without
DNA who had close relatives that had been genotyped.
These cases were assigned in silico genotypes, corresponding
to an effective sample size of approximately 350 cases and
3500 controls who were also in silico genotyped [see the
section In silico genotyping (Iceland III)].
Study subjects from the Netherlands
The Dutch patients were recruited for the Nijmegen Bladder
Cancer Study (NBCS: http://dceg.cancer.gov/icbc/mem
bership.html). The NBCS identified patients through the
population-based regional cancer registry held by the Compre-
hensive Cancer Centre East, Nijmegen, that serves a region of
1.3 million inhabitants in the eastern part of the Netherlands
(www.ikcnet.nl). Patients diagnosed between 1995 and 2006
under the age of 75 years were selected and their vital status
and current addresses updated through the hospital infor-
mation systems of the seven community hospitals and one uni-
versity hospital (Radboud University Nijmegen Medical
Centre, RUNMC) that are covered by the cancer registry.
All patients still alive on 1 August 2007 were invited to the
study by the Comprehensive Cancer Center on behalf of the
patients’ treating physicians. A second group of patients, diag-
nosed between 2007 and 2008, was invited in 2009. In case of
consent, patients were sent a lifestyle questionnaire to fill out
and blood samples were collected by Thrombosis Service
centers which hold offices in all the communities in the
region. In total, 1940 patients were invited to participate. Of
all the invitees, 1275 gave informed consent (66%): 1185
filled out the questionnaire (61%) and 1219 (63%) provided
a blood sample. The number of participating patients was
increased with a non-overlapping series of 439 bladder
cancer patients who were recruited previously for a study on
gene–environment interactions in three hospitals (RUNMC,
Canisius Wilhelmina Hospital, Nijmegen, and Streekzieken-
huis Midden-Twente, Hengelo, the Netherlands). Ultimately,
completed questionnaires and blood samples were available
for 1429 and 1691 patients, respectively. All the patients
selected for the analyses (n ¼ 1631) were of self-reported
European descent. The median age at diagnosis was 62
(range 25–93) years. Eighty-two percent of the participants
were males. Data on tumor stage and grade were obtained
through the cancer registry.
The control group (n ¼ 3822) came from different sources. A
total of 1918 cancer-free control individuals (46% males) were
recruited within a project entitled ‘Nijmegen biomedical study’
(NBS). The details of this study were reported previously (29).
Briefly, this is a population-based survey conducted by the
Department of Epidemiology and Biostatistics and the
Department of Clinical Chemistry of the RUNMC, in which
9371 individuals participated from a total of 22 500 age- and
sex-stratified, randomly selected inhabitants of Nijmegen.
Control individuals from the NBS were invited to participate
in a study on gene–environment interactions in multifactorial
diseases such as cancer. They were all of self-reported Euro-
pean descent and fully informed about the goals and the pro-
cedures of the study. The study protocols of the NBCS and
the NBS were approved by the Institutional Review Board of
the RUNMC and all study subjects gave written informed
consent. The NBS control group was extended with a Dutch
control group provided by collaborators from the University
of Utrecht that had been chip-genotyped in conjunction with
other studies and have been described in a previous publication
(30). Briefly, these controls were recruited from two sources: (i)
613 control individuals were unrelated, healthy volunteers who
accompanied non-amyotrophic lateral sclerosis (ALS) patients
to the University Medical Center Utrecht neurology outpatient
clinic, (ii) 1358 individuals were included from a GWAS on
schizophrenia. All were of Dutch descent, with at least three
out of four grandparents of Dutch ancestry. Of the 3881 chip-
typed controls, 3822 passed all quality control filters and
were used for analysis.
Study subjects from the UK
Details of the Leeds Bladder Cancer Study have been reported
previously (31). In brief, patients from the urology department
of St James’s University Hospital, Leeds, were recruited from
August 2002 to March 2006. All patients undergoing cysto-
scopy or transurethral resection of a bladder tumor who had
previously been found, or were subsequently shown, to have
urothelial cell carcinoma of the bladder were included. Exclu-
sion criterion was significant mental impairment or a blood
transfusion in the past month. All non-Caucasians were
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excluded from the study, leaving 764 patients. The median age
at diagnosis of the patients was 73 years (range 30–101).
Seventy-one percent of the patients were male and 36% of all
the patients had tumors with low risk of progression (pTaG1/
2). The controls were recruited from the otolaryngology outpa-
tients and ophthalmology inpatient and outpatient departments
at St James’s Hospital, Leeds, from August 2002 to March
2006. All controls of appropriate age for frequency-matching
with the cases were approached and recruited. As for the
cases, exclusion criteria for the controls were significant
mental impairment or a blood transfusion in the past month.
Also, controls were excluded if they had symptoms suggestive
of bladder cancer, such as hematuria; 2.8% of the controls were
non-Caucasian, leaving 530 Caucasian controls for the study,
and 71% of the controls were male. Data were collected by a
health questionnaire on smoking habits and smoking history
(non-, ex- or current smoker, smoking dose in pack-years),
occupational exposure history (to plastics, rubber, laboratories,
printing, dyes and paints, diesel fumes), family history of
bladder cancer, ethnicity and place of birth and places of
birth of parents. The participation rate of cases was 99%,
and that among the controls was 80%. Ethical approval for
the study was obtained from Leeds (East) Local Research
Ethics Committee, project number 02/192.
Study subjects from Torino, Italy
The sources of cases for the Torino bladder cancer study were
two urology departments of the main hospital in Torino, the
San Giovanni Battista Hospital (32). Cases were all Caucasian
men, aged 40–75 years (median 63 years) and living in the
Torino metropolitan area. They were newly diagnosed
between 1994 and 2006 with a histologically confirmed, inva-
sive or in situ, bladder cancer. Of all the patients with infor-
mation on stage and grade, 56% were at low risk of
progression (pTaG1/2). The sources of controls are urology,
medical and surgical departments of the same hospital in
Torino. All controls are Caucasian men resident in the
Torino metropolitan area. They were diagnosed and treated
between 1994 and 2006 for benign diseases (such as prostatic
hyperplasia, cystitis, hernias, heart failure, asthma and benign
ear diseases). Controls with cancer, liver or renal diseases and
smoking-related conditions were excluded. The median age of
the controls was 57 years (range 40–74). Data were collected
by a professional interviewer who used a structured question-
naire to interview both cases and controls face-to-face. Data
collected included demographics (age, sex, ethnicity, region
and education) and smoking. For cases, additional data were
collected on tumor histology, tumor site, size, stage, grade
and treatment of the primary tumor. The participation rates
were 90% for cases and 75% for controls, resulting in 328
cases and 389 controls. Ethical approval for the study was
obtained from Comitato Etico Interaziendale, A.O.U. San
Giovanni Battista/C.T.O./Maria Adelaide.
Study subjects from Brescia, Italy
The Brescia bladder cancer study is a hospital-based
case–control study. The study was reported in detail pre-
viously (33). In short, the catchment area of the cases and
controls was the Province of Brescia, a highly industrialized
area in Northern Italy (mainly metal and mechanical industry,
construction, transport, textiles) but also with relevant agricul-
tural areas. Cases and controls were enrolled in 1997–2000
from the two main city hospitals. The total number of eligible
subjects was 216 cases and 220 controls. The participation rate
(enrolled/eligible) was 93% (n ¼ 201) for cases and 97% (n ¼
214) for controls. Only males were included. All cases and
controls had Italian nationality and were of Caucasian ethni-
city. All cases had to be residents of the Province of
Brescia, aged between 20 and 80, and newly diagnosed with
histologically confirmed bladder cancer. The median age of
the patients was 63 years (range 22–80); 29% of all the
patients with known stage and grade had tumors of low risk
of progression (pTaG1/2). Controls were patients admitted
for various urological non-neoplastic diseases and were
frequency-matched to cases on age, hospital and period of
admission. The study was formally approved by the ethical
committee of the hospital where the majority of subjects
were recruited. A written informed consent was obtained
from all participants. Data were collected from clinical
charts (tumor histology, site, grade, stage, treatments, etc.)
and by means of face-to-face interviews during hospital
admission, using a standardized semi-structured questionnaire.
The questionnaire included data on demographics (age, ethni-
city, region, education, residence, etc.) and smoking. ISCO
and ISIC codes and expert assessments were used for occu-
pational coding. Blood samples were collected from cases
and controls for genotyping and DNA adduct analyses.
Study subjects from Belgium
The Belgian study has been reported in detail (34). In brief,
cases were selected from the Limburg Cancer Registry
(LIKAR) and were approached through urologists and
general practitioners. All cases were diagnosed with histologi-
cally confirmed urothelial cell carcinoma of the bladder
between 1999 and 2004, and were Caucasian inhabitants of
the Belgian province of Limburg. The median age of the
patients was 68 years, and 86% of all the patients were
males. For the recruitment of controls, a request was made
to the ‘Kruispuntbank’ of the social security for simple
random sampling, stratified by municipality and socio-
economic status, among all citizens .50 years of age of the
province. The median age of the controls was 64 years; 59%
of the controls were males. Three trained interviewers
visited cases and controls at home. Information was collected
through a structured interview and a standardized food fre-
quency questionnaire. In addition, biological samples were
collected. Data collected included medical history, lifetime
smoking history, family history of bladder cancer and a life-
time occupational history. Informed consent was obtained
from all participants and the study was approved by the
ethical review board of the Medical School of the Catholic
University of Leuven, Belgium.
Study subjects from Eastern Europe
The details of this study have been described previously (35).
Cases and controls were recruited as part of a study designed
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to evaluate the risk of various cancers due to environmental
arsenic exposure in Hungary, Romania and Slovakia between
2002 and 2004. The recruitment was carried out in the counties
of Bacs, Bekes, Csongrad and Jasz-Nagykun-Szolnok in
Hungary; Bihor and Arad in Romania; and Banska Bystrica
and Nitra in Slovakia. The cases (n ¼ 214) and controls
(n ¼ 533) selected were of Hungarian, Romanian and Slovak
nationalities. Bladder cancer patients were invited on the basis
of histopathological examinations by pathologists. Hospital-
based controls were included in the study, subject to fulfillment
of a set of criteria. All general hospitals in the study areas were
involved in the process of control recruitment. The controls were
frequency-matched with cases for age, gender, country of resi-
dence and ethnicity. Controls included general surgery, orthope-
dic and trauma patients aged 30–79 years. Patients with
malignant tumors, diabetes and cardiovascular diseases were
excluded as controls. The median age of the bladder cancer
patients was 65 years (range 36–90). Eighty-three percent of
the patients were males. The median age for the controls was
61 years (range 28–83). Fifty-one percent of the controls were
males. The participation rates among cases and controls were
70%. Of all the patients with known stage and grade infor-
mation, 28% had a low-risk tumor (pTaG1/2). Clinicians took
venous blood and other biological samples from cases and con-
trols after consent forms had been signed. Cases and controls
recruited to the study were interviewed by trained personnel
and completed a general lifestyle questionnaire. Ethnic back-
ground for cases and controls was recorded along with other
characteristics of the study population. Local ethical boards
approved the study plan and design.
Study subjects from Sweden
The Swedish patients came from a population-based study of
UBC patients diagnosed in the Stockholm region in
1995–1996 (36). Blood samples from 352 patients were avail-
able out of a collection of 538 patients with primary urothelial
carcinoma of the bladder. The average age at onset for these
patients was 69 years (range 32–97 years) and 67% of the
patients were males. Clinical data, including age at onset,
grade and stage of tumor, were prospectively obtained from
hospitals and urology units in the region. The control
samples came from blood donors in the Stockholm region
and were from cancer-free individuals of both genders. The
regional ethical committee approved of the study and all par-
ticipants gave informed consent.
Study subjects from Spain
The Spanish study patients were recruited from the urology
and oncology departments of Zaragoza Hospital between Sep-
tember 2007 and June 2009. A total of 246 patients with his-
tologically proven urothelial cell carcinoma of the bladder
were enrolled (response 77%). Clinical information including
age at onset, grade and stage was obtained from medical
records. The median age at diagnosis for the patients was 65
years (range 27–94) and 87% were males. The 890 Spanish
control individuals were part of a larger collection of control
samples obtained from individuals who had attended the Uni-
versity Hospital in Zaragoza, Spain, for diseases other than
cancer between November 2001 and May 2007. The controls
were of both genders and median age was 52 years (range
11–87). Controls were questioned to rule out prior cancers
before drawing the blood sample. All patients and controls
were of self-reported European descent. Study protocols
were approved by the Institutional Review Board of Zaragoza
University Hospital. All subjects gave written informed
consent.
Study subjects from Germany
The study subjects from Germany came from three different
studies.
(i) The Neuss bladder cancer study. Details of the bladder
cancer cases of this study have been published previously
(37). The ongoing case–control series consists of 217
bladder cancer cases and 105 controls from the Depart-
ment of Urology, Lukasklinik Neuss, Germany, located
20 km from the Ruhr area. The median age at diagnosis
was 72.9 (range 26.1–93.4) years. Seventy-eight percent
of the participants were males. Data on tumor stage and
grade were obtained through the cancer registry.
Forty-five percent of the patients had a low-risk tumor
(pTaG1/2). The 105 control individuals (64% males)
(median age 42.4, range 18.0–89.0) were cancer-free.
Data were collected from June 2009 to July 2010. The
local ethics committee approved the study plan and
design.
(ii) The Dortmund bladder cancer study. Details of the
bladder cancer cases of this study have been published
previously (37). The case–control series consists of 197
patients with a confirmed bladder cancer from the
Department of Urology, St.-Josefs-Hospital Dortmund-
Ho¨rde, located in the Ruhr area, an area of former coal,
iron and steel industries and 240 controls from the
same Department of Urology, admitted for treatment of
benign urological diseases, enrolled from July 2009 to
July 2010. The median age at diagnosis was 71.2
(range 35.0–89.2) years. Seventy-five percent of the par-
ticipants were males, and 60% of the patients had tumors
with low risk of progression (pTaG1/2). The 240 control
individuals (77% males) were cancer-free and frequency-
matched for age with the cases (median age 70.7, range
21.7–100). The local ethics committee approved the
study plan and design.
(iii) The Lutherstadt Wittenberg (LW) study. Details of the
bladder cancer cases of this study have been reported pre-
viously (37–39). In brief, 221 patients with a confirmed
bladder cancer from the Department of Urology, Paul
Gerhardt Foundation, Lutherstadt Wittenberg, Germany,
were included. Patients were enrolled from December
1995 to January 1999. Exclusion criterion was a
missing written informed consent into the study. The
median age of the patients was 65 years (range 20–91);
86% of the patients were males. A total of 214 controls
were from the same Department of Urology, but were
admitted for treatment of benign urological diseases.
Exclusion criterion was a malignant disease in the
medical history or a missing written informed consent.
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The median age of the controls was 68 years (range 29–
91); 84% of the controls were males. Data were collected
from July 2000 to May 2005. All cases and controls were
Caucasians, which was confirmed by questionnaire-based
documentation of nationality. Cases and controls were
matched for age. Data collected in cases and controls
include age, gender, a complete documentation of occu-
pational activities performed at least for 6 months, docu-
mentation of work places with known bladder cancer risk
over the entire working life, exposures to known or sus-
pected occupational bladder carcinogens, lifetime
smoking habits, family history of bladder cancer,
numbers of urinary infections treated by drugs during
the previous 10 years, place of birth and places of resi-
dency for .10 years. For bladder cancer cases, data on
tumor staging, grading and treatment were taken from
the records. First diagnosis of bladder cancer was
recorded from July 1979 to January 1999. The local
ethics committee approved the study plan and design.
Study subjects from Iran
Samples from Iranian bladder cancer patients were obtained
from the Biobank of Shiraz Institute for Cancer Research
(http://icr.ir/groups/biobank.html). The majority of the
patients were residents of the province of Fars (of which
Shiraz is the capital city) in the south of Iran. The people of
Fars are Persian with little racial heterogeneity. However,
since hospitals affiliated with Shiraz University of Medical
Sciences are referral hospitals for large parts of southern
Iran, inclusion of patients from other ethnic groups cannot
be ruled out. The DNA collection of all cancer patients in
the Biobank of Shiraz Institute for Cancer Research is an
ongoing process that started in 1999. For the present study,
267 patients (229 males and 38 females) with histologically
verified bladder cancer were available. The mean ages at diag-
nosis were 63.6 and 60.1 years, respectively. For 3% of all
cases, age could not be determined. The majority of the
patients had urothelial cell carcinoma (n ¼ 239; 89.5%); the
remaining had squamous cell carcinoma, adenocarcinoma,
rhabdomyosarcoma or unspecified/unknown morphology.
The control group consisted of 222 male and 25 female
healthy Iranian subjects without apparent cancer or auto-
immune diseases and a negative first-degree family history
of cancer. The controls were recruited among healthy blood
donors at the Fars blood transfusion center. The mean ages
were 54.0 years for males and 53.5 years for females. DNA
of the controls was also obtained from the Biobank of
Shiraz Institute for Cancer Research. Informed consent was
obtained from all patients and controls. The biobanking pro-
cedures have been approved by Shiraz University of Medical
Sciences Ethics Committee.
Illumina genome-wide genotyping
The Dutch and Icelandic case and control samples were assayed
with the Illumina HumanHap300 or HumanHapCNV370 bead
chips (Illumina, San Diego, CA, USA), containing 317 503
and 370 404 haplotype tagging SNPs derived from phase I of
the International HapMap project, respectively. SNPs were
excluded if they had: (i) a yield ,95% in cases or controls;
(ii) a minor allele frequency ,1% in the population; or (iii)
showed significant deviation from Hardy–Weinberg equili-
brium in the controls (P , 0.001). Any samples with a call
rate ,98% were excluded from the analysis.
SNP imputations
For the Dutch data set, we used 292 650 autosomal SNPs
present on both chip types to impute an additional 7 543 837
ungenotyped SNPs using the IMPUTE v2.1 software (40,41)
and a training set consisting of the combined 1000 Genomes
low-coverage pilot haplotypes (released June 2010, 120
chromosomes) and the HapMap3 haplotypes (released Febru-
ary 2009, 1920 chromosomes) downloaded from http://ma
thgen.stats.ox.ac.uk/impute/impute_v2.html#filtered_1kg_hm
3_haps. Individuals with ,96% yield for the 292 650 SNPs
and SNPs with minor allele frequency ,0.01, which were
not in Hardy–Weinberg equilibrium (P , 1025) or with a
different frequency for the two chip types used (P , 1025),
were excluded from the imputation. For the Icelandic data
set, we used 289 572 autosomal SNPs to impute an additional
11 283 069 ungenotyped SNPs using as training set the 566
phased European haplotypes of the August 2010 release of
the 1000 Genomes project, downloaded from http://mathgen.
stats.ox.ac.uk/impute/impute_v2.html#August_haps. The
imputation method used for the Icelandic data set has been
described previously (42). In short, it is an adaption of the
methodology as used in the IMPUTE software but taking
advantage of the long-range phasing of the whole Icelandic
data set. As for the Dutch data set, individuals with low
yield and SNPs that failed quality control were excluded
prior to imputation.
Genome-wide analysis
For both the Icelandic and the Dutch data set, we used
SNPTEST v2.1.1 (41) to test each SNP for association with
bladder cancer, assuming additive genetic effect and using
missing data likelihood score test (the method score option)
to account for imputation uncertainty. Individuals with geno-
type yield ,98% and SNPs with information (proper_info)
,0.4 in the analysis of either data set were excluded. When
combining the two data sets, we restricted the analysis to
SNPs that were present in both data sets and that had MAF
.1%. As the August 2010 release of the 1000 Genomes is
mapped to NCBI Genome build 37, the location of those
SNPs were mapped to build 36 using the UCSC LiftOver
tool (http://genome.ucsc.edu/cgi-bin/hgLiftOver). A total of
5 340 737 SNPs that passed quality criteria and that were
identified in both data sets were included when the results
for the two data sets were combined.
Prior to combining the two data sets, the results were
adjusted using the method of genomic control by dividing
the x2 statistics by 1.071 for the Dutch data set and by
1.011 for the Icelandic data set. For the combined analysis,
we assumed a fixed effect model implemented in the
program METAL (http://www.sph.umich.edu/csg/abecasis/
Metal/) and weighted the contribution of each data set with
the corresponding standard error. Heterogeneity in the effect
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estimate for each SNP was calculated by including the corre-
sponding option in METAL.
Single-SNP genotyping
Single-SNP genotyping for all samples was carried out at
deCODE Genetics in Reykjavik, Iceland, applying the same
platform to all populations studied. All single-SNP genotyping
was carried out using the Centaurus (Nanogen) platform (43).
The quality of each Centaurus SNP assay was evaluated by gen-
otyping each assay on the CEU samples and comparing the
results with the HapMap data (44). All assays had mismatch
rate ,0.5%. Additionally, all markers were re-genotyped on
.10% of samples typed with the Illumina platform, resulting
in an observed mismatch in ,0.5% of samples.
In silico genotyping (Iceland III)
In addition to imputing rs1058396 and rs17674580 into chip-
genotyped individuals, we also performed a second imputation
step where genotypes were imputed into relatives of chip-
genotyped individuals, creating in silico genotypes. The
inputs into the second imputation step are the fully phased
(in particular, every allele has been assigned a parent of
origin) imputed and chip-typed genotypes of the available
chip-typed individuals. The algorithm used to perform the
second imputation step consists of:
(i) For each ungenotyped individual (the proband), find all
chip-genotyped individuals within two meioses of the
individual. The six possible types of two-meioses rela-
tives of the proband are (ignoring more complicated
relationships due to pedigree loops) parents, full and
half siblings, grandparents, children and grandchildren.
If all pedigree paths from the proband to a genotyped
relative go through other genotyped relatives, then that
relative is excluded. For example, if a parent of the
proband is genotyped, then the proband’s grandparents
through that parent are excluded. If the number of
meioses in the pedigree around the proband exceeds a
threshold (we used 12), then relatives are removed
from the pedigree until the number of meioses falls
below 12, in order to reduce computational complexity.
(ii) At every point in the genome, calculate the probability
for each genotyped relative sharing with the proband
based on the autosomal SNPs used for phasing. A multi-
point algorithm, based on the hidden Markov-model
Lander–Green multipoint linkage algorithm using fast
Fourier transforms, is used to calculate these sharing
probabilities (10,45,46). First, single-point sharing prob-
abilities are calculated by dividing the genome into
0.5 cM bins and using the haplotypes over these bins as
alleles. Haplotypes that are the same, except that they
can differ for one SNP at most, are treated as identical.
When the haplotypes in the pedigree are incompatible
over a bin, then a uniform probability distribution was
used for that bin. The most common causes for such
incompatibilities are recombinations within the pedigree,
phasing errors and genotyping errors. Note that since the
input genotypes are fully phased, the single-point
information is substantially more informative than for
unphased genotyped persons. In particular one haplotype
of the parent of a genotyped child is always known. The
single-point distributions are then convolved using the
multipoint algorithm to obtain multipoint sharing prob-
abilities at the center of each bin. Genetic distances
were obtained from the most recent version of the
deCODE genetic map (47).
(iii) Based on the sharing probabilities at the center of each
bin, all the SNPs from the whole-genome genotyping
are imputed into the proband. To impute the genotype
of the paternal allele of an SNP located at x, flanked by
bins with centers at xleft and xright, starting with the left
bin, going through all possible sharing patterns n, let In
be the set of haplotypes of genotyped individuals that
share identically by descent within the pedigree with
the proband’s paternal haplotype given the sharing
pattern n and P(n) be the probability of n at the left
bin—this is the output from step (ii) above—and let ei
be the expected allele count of the SNP for haplotype i.
Then ev =
∑
i[Iv[i
/
∑
i[Iv1
is the expected allele count
of the paternal haplotype of the proband given n and an
overall estimate of the allele count given the sharing dis-
tribution at the left bin is obtained from eleft =
∑
vP v( )ev .
If In is empty, then no relative shares with the proband’s
paternal haplotype given n and thus there is no infor-
mation about the allele count. We therefore store the
probability that some genotyped relative shared the pro-
band’s paternal haplotype, Oleft =
∑
v,Iv=f P(V ), and an
expected allele count, conditional on the proband’s
paternal haplotype being shared by at least one genotyped
relative: Cleft =
∑
v,Iv=f
P(v)ev/
∑
v,Iv=f
P(v). In the
same way, calculate Oright and Cright. Linear interpolation
is then used to get an estimate at the SNP from the two
flanking bins:
O = Oleft + x− xleft
xright − xleft (Oright − Oleft),
C = Cleft + x− xleft
xright − xleft (Cright − Cleft).
If u is an estimate of the population frequency of the SNP, then
Oc + (1 – O)u is an estimate of the allele count for the pro-
band’s paternal haplotype. Similarly, an expected allele
count can be obtained for the proband’s maternal haplotype.
When performing case–control analysis with the in silico
genotypes, we use logistic regression to test for association
between SNPs and disease, treating disease status as the
response and expected genotype counts from imputation or
allele counts from direct genotyping as covariates. Testing
was performed using the likelihood ratio statistic. When
testing for association based on the in silico genotypes, con-
trols were matched to cases based on the informativeness of
the imputed genotypes, such that for each case C, controls
of matching informativeness were chosen. Failing to match
cases and controls will lead to a highly inflated genomic
control factor, and in some cases may lead to spurious false-
positive findings. The informativeness of each of the
Human Molecular Genetics, 2011 11
 by guest on June 1, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
imputation of each one of an individual’s haplotypes was esti-
mated by taking the average of
a(e, u) =
e− u
1− u e ≥ u
u− e
u
e , u
⎧⎪⎨
⎪⎩
over all SNPs imputed for the individual, where e is the
expected allele count for the haplotype at the SNP and u is
the population frequency of the SNP. Note that a(u,u) ¼ 0
and a(0,u) ¼ a(1,u) ¼ 1. The mean informativeness values
cluster into groups corresponding to the most common pedi-
gree configurations used in the imputation, such as imputing
from parent into child or from child into parent. Based on
this clustering of imputation informativeness, we divided the
haplotypes of individuals into 7 groups of varying informa-
tiveness, which created 27 groups of individuals of similar
imputation informativeness; 7 groups of individuals with
both haplotypes having similar informativeness, 21 groups
of individuals with the two haplotypes having different infor-
mativeness, minus the one group of individuals with neither
haplotype being imputed well. Within each group, we calcu-
late the ratio of the number of controls and the number of
cases, and choose the largest integer C that was less than
this ratio in all the groups. For example, if in one group
there are 10.3 times as many controls as cases and if in all
other groups this ratio was greater, then we would set
C ¼ 10 and within each group randomly select 10 times as
many controls as there are cases.
Association analysis
For association analysis of the replication data sets, we used a
standard likelihood ratio statistic, implemented in the NEMO
software (48) to calculate two-sided P-values for each individ-
ual allele, assuming a multiplicative model for UBC risk, i.e.
the relative risk from carrying two copies of the high-risk
allele (compared with none) is assumed to be the square of
the relative risk from carrying one copy. Results from multiple
case–control groups were combined using a Mantel–Haenszel
model in which the groups were allowed to have different
population frequencies for alleles and genotypes but were
assumed to have common ORs. Stratified analyses were con-
ducted by smoking and by UBC aggressiveness. For the
latter, all patients for whom detailed histology information
was available were classified with regard to risk of pro-
gression, based on stage and grade information. Patients
with ‘low risk of progression’ were defined as having TNM
stage pTa in combination with WHO 1973 differentiation
grade 1 or 2 or WHO/ISUP 2004 low grade. All other
tumors were classified as ‘high risk of progression’ (stage
pTis or ≥ pT1 or WHO 1973 grade 3 or WHO/ISUP 2004
high grade).
Heterogeneity calculations
Heterogeneity was tested by comparing the null hypothesis of
the effect being the same in all populations to the alternative
hypothesis of each population having a different effect using
a likelihood ratio test. I2 lies between 0 and 100% and
describes the proportion of total variation in study estimates
that is due to heterogeneity (49).
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